Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFARI: Switching from Aflibercept to Ranibizumab in nAMD
NCT02161575Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2014
- Primary completion
- Sep 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Aug 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02161575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161575.